Shotsy, the most downloaded GLP-1 tracking app on the market, today announced the launch of Shotsy 3.0. The release introduces new oral GLP-1 pill-tracking options, estimated medication level charts to support personalized dosing, a first-of-its-kind Maintenance Mode for patients who have reached their goal weight, and a new multi-medication scheduling system designed for the growing complexity of modern GLP-1 therapy.
The update arrives at a pivotal moment for the nearly one in eight U.S. adults who have now used a GLP-1 medication and face mounting challenges in their journeys. Despite the explosive growth of GLP-1 therapy, up to 65% of patients discontinue within the first year, with side effects, rising costs, and lack of support listed among the leading reasons for terminating their use.
"GLP-1 therapy is evolving faster than the support systems around it, and patients are largely left to navigate that complexity on their own," said Aja Beckett, CEO and founder of Shotsy. "Shotsy 3.0 was designed to arm patients with the data and tools required to be active participants in their own care. By closing the support gap, we can give patients what they need to be informed, stay on track, and succeed long term."
As oral GLP-1 medications enter the market and combination therapy becomes more common, patients are navigating increasingly complex regimens with little structured support. Shotsy 3.0 was built to meet that evolving reality, and users can now expect the previously available features, as well as these new updates, bringing continued, evolving support for managing complex, multi-drug regimens.
What's New in Shotsy 3.0
Shotsy 3.0 gives patients the most complete GLP-1 tracking experience available, including:
- Oral GLP-1 tracking with Estimated Medication Level charts reflecting the latest clinical data for the Wegovy pill and other oral medications.
- Maintenance Mode, a first-of-its-kind feature that helps users transition from active weight loss to long-term maintenance after reaching their goal.
- Multi-medication scheduling with separate countdowns, reminders, and tracking for concurrent medication types.
- Expanded medication support, now including Trulicity, Saxenda, Victoza, and Rybelsus, in addition to Ozempic®, Wegovy®, Mounjaro®, and Zepbound®.
"We are in the early innings of a new era in metabolic disease management, and oral GLP-1 medications will significantly expand the population who can benefit from this drug class,” said Eric Perakslis, Chief Science Officer at Shotsy. “Shotsy 3.0 does ensure the patient-facing tools evolve at the same pace as the science, providing experienced and data-driven tracking that empowers patients to engage more meaningfully in their own care, from initiation through long-term maintenance."
To access Shotsy 3.0, visit the iOS or Android app store. The app is free to download, with premium features available via subscription.
About Shotsy
Shotsy is the most downloaded GLP-1 tracking app on the market, with nearly one million downloads across iOS and Android. Founded in 2024 by Aja Beckett, a software engineer and GLP-1 patient herself, Shotsy was built to close the support gap that leaves millions of patients navigating complex medication journeys largely on their own. The app provides a comprehensive, science-backed platform where patients can log injections, track side effects, monitor health metrics, and view detailed progress charts — all designed to make them active, informed participants in their own care. Shotsy supports all major GLP-1 medications, including Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. Backed by investors including Coalition Operators, Adverb Ventures, and Springbank Collective, Shotsy is headquartered in Portland, Oregon. Learn more at shotsyapp.com.
Disclaimer
Shotsy does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any medical decisions.
Media Contact
Abby McAdams
abby@asmcomms.com
